|
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 19633
© 2007 American Society of Clinical Oncology
RESPOND - Raising awareness of anemia in oncology centers through computer algorithm driven guidelines: Assessment of intraclass correlation metrics for the accuracy of algorithmic definitions
J. Foubert,
M. Aapro,
P. Soubeyran,
C. Bokemeyer,
J. Van Erps,
M. Muenzberg,
M. Turner,
K. MacDonald and
I. Abraham
Institut Jules Bordet, Brussels, Belgium; Clinique de Genolier, Genolier, Switzerland; Institut Bergonie, Bordeaux, France; University Hospital Hamburg, Hamburg, Germany; Algemeen Stedelijk Ziekenhuis Aalst, Alast, Belgium; F. Hoffmann-La Roche, Basel, Switzerland; Roche, Welwyn Garden City, United Kingdom; Matrix45, Earlysville, VA
19633
Background: Publication of evidence-based (EB) practice guidelines (EBPGs) does not assure their application in patient care. Computerized clinical decision support systems (CDSSs) incorporating EBPGs may promote EB decision-making about individual patients. Most CDSSs are knowledge-, not evidence-based. Effective CDSSs are those integrated into workflow, providing point of care guidance, and offering actionable recommendations. Few are validated in terms of algorithmic operationalization. RESPOND is a CDSS based on the 2006 update of the European Organisation for Research and Treatment of Cancer (EORTC) EBPGs for erythropoietic proteins in cancer-related anemia. Method: Descriptive study. Panel of five experts (three physicians, two nurses) rated the 27 algorithms derived from the EORTC EBPGs in terms of accuracy (binary: yes/no). If not judged accurate, experts were asked to explain and propose correction. Objective was to attain intraclass correlation coefficient (ICC) >0.90 for each operationalization in a maximum of three iterations. Table 1. Example of operationalization of guideline Hb, hemoglobin Results: In iteration 1, three experts agreed with all 27 sets; one disagreed with one set and one with four sets; therefore ICC = 1.00 for 22 sets; 0.90 for five sets. Three sets concerned additional output to be generated, and one a substantive inaccuracy; all were corrected. One set concerned a suggestion not supported by evidence, hence not incorporated. In iteration 2, all five experts agreed with all sets, thus ICC = 1.00 for 27 sets. Conclusions: The RESPOND CDSS being developed and validated is based on algorithms that accurately specify, in the form of conditional dependency rules, the EORTC EBPGs for erythropoietic proteins.
Author Disclosure
| Employment or Leadership |
Consultant or Advisory |
Stock Ownership |
Honoraria |
Research |
Expert Testimony |
Other Remuneration |
|
| Roche |
Amgen, Baxter Oncology, EONS, Johnson&Johnson, Roche, Schering AG |
|
Amgen, Baxter Oncology, Bristol-Myers Squibb, Chugai Pharma USA, Gilead, Johnson&Johnson, Ortho Biotech, Roche, sanofi-aventis, Schering AG, Schering-Plough |
Roche |
|
EONS |
|
|